Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.

HIV-1, hepatitis B virus, hepatitis C virus, and human papillomavirus type 16 cause persistent infections that frequently precede cancer development. Virions of these viruses are weak inducers of interferon-α and impair Toll-like receptor (TLR)9 function. Loss of TLR9 responsiveness also occurs in tumors without viral etiology such as breast, ovary, and head and neck carcinomas. Recent reports have suggested that viruses and components of the tumor microenviroment interact with regulatory receptors on plasmacytoid dendritic cells (pDCs) to impair TLR7 and TLR9 signaling, and to downregulate TLR9 gene expression. The limited responsiveness of pDCs might contribute to reduced innate immune responses during chronic viral infections and oncogenesis, and represent a target for new therapeutic approaches based on TLR agonists.

[1]  John Guatelli,et al.  Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. , 2009, AIDS research and human retroviruses.

[2]  J. Lifson,et al.  Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. , 2005, The Journal of clinical investigation.

[3]  D. Palli,et al.  Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. , 2007, Clinical immunology.

[4]  T. Santantonio,et al.  Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection , 2005, Hepatology.

[5]  Jie Cao,et al.  Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis , 2009, BMC Cancer.

[6]  L. Lanier,et al.  Inhibition of Immune Responses by ITAM-Bearing Receptors , 2006, Science's STKE.

[7]  K. Honda,et al.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. , 2003, Nature.

[8]  Jennifer Louten,et al.  Cutting Edge: Peyer’s Patch Plasmacytoid Dendritic Cells (pDCs) Produce Low Levels of Type I Interferons: Possible Role for IL-10, TGFβ, and Prostaglandin E2 in Conditioning a Unique Mucosal pDC Phenotype1 , 2007, The Journal of Immunology.

[9]  M. Grace,et al.  Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.

[10]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[11]  Zhan-qing Zhang,et al.  HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. , 2009, Molecular immunology.

[12]  K. Honda,et al.  Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction , 2005, Nature.

[13]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[14]  Tomoki Ito,et al.  Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells , 2006, Immunology.

[15]  A. Fauci,et al.  HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells , 2007, Proceedings of the National Academy of Sciences.

[16]  D. Olive,et al.  Hepatitis C Virus Is a Weak Inducer of Interferon Alpha in Plasmacytoid Dendritic Cells in Comparison with Influenza and Human Herpesvirus Type-1 , 2009, PloS one.

[17]  S. Maschalidi,et al.  Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. , 2009, Immunity.

[18]  M. Shiina,et al.  Cell culture–produced hepatitis C virus impairs plasmacytoid dendritic cell function , 2007, Hepatology.

[19]  T. Molina,et al.  Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. , 2009, Blood.

[20]  T. Iftner,et al.  TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 , 2007, The Journal of Immunology.

[21]  J. Blay,et al.  Breast tumor environment inhibits human plasmacytoid dendritic cell functions , 2008 .

[22]  M. Stanley,et al.  A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. , 1998, The Journal of infectious diseases.

[23]  V. Pascual,et al.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.

[24]  M. Tremblay,et al.  The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. , 2008, Blood.

[25]  F. Chisari,et al.  Plasmacytoid dendritic cells sense hepatitis C virus–infected cells, produce interferon, and inhibit infection , 2010, Proceedings of the National Academy of Sciences.

[26]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[27]  C. Melief,et al.  Dendritic cells in cancer immunotherapy. , 2008, Advances in cancer research.

[28]  A. Fauci,et al.  HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Bardot,et al.  Enhanced tumor development in mice lacking a functional type I interferon receptor. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[30]  Toshio Matsumoto,et al.  Interferon‐α enhances CD317 expression and the antitumor activity of anti‐CD317 monoclonal antibody in renal cell carcinoma xenograft models , 2008, Cancer science.

[31]  A. Dolganiuc,et al.  Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-α and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection1 , 2006, The Journal of Immunology.

[32]  B. Bacon,et al.  Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus , 2007, Hepatology.

[33]  T. Berg,et al.  Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection , 2005, Hepatology.

[34]  T. Kopp,et al.  Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells , 2007, The Journal of experimental medicine.

[35]  M. Amjad,et al.  Decreased interferon‐α production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein , 2008, Microbiology and immunology.

[36]  L. Lanier,et al.  Regulation of TLR 7 / 9 responses in plasmacytoid dendritic cells by BST 2 and ILT 7 receptor interaction , 2009 .

[37]  T. Bieber,et al.  Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. , 2005, American journal of clinical pathology.

[38]  B. Zhivotovsky,et al.  Mechanisms of Interferon-alpha induced apoptosis in malignant cells , 2002, Oncogene.

[39]  W. Zou,et al.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. , 2008, Molecular cell.

[40]  Xuetao Cao,et al.  Splenic Stromal Microenvironment Negatively Regulates Virus-Activated Plasmacytoid Dendritic Cells through TGF-β1 , 2008, The Journal of Immunology.

[41]  G. Van Nest,et al.  Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. , 2007, Journal of leukocyte biology.

[42]  A. Vicari,et al.  Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist , 2007, Antiviral therapy.

[43]  Wei Wang,et al.  HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody , 2009, Cancer Immunology, Immunotherapy.

[44]  J. McHutchison,et al.  Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. , 2007, Journal of hepatology.

[45]  S. Akira,et al.  Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines , 2007, Journal of Virology.

[46]  Wei Cao,et al.  Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production , 2006 .

[47]  M. Colonna,et al.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance , 2010, Immunological reviews.

[48]  T. Mak,et al.  Adhesive mechanisms governing interferon-producing cell recruitment into lymph nodes , 2005, The Journal of experimental medicine.

[49]  L. Lanier,et al.  BDCA2/FcɛRIγ Complex Signals through a Novel BCR-Like Pathway in Human Plasmacytoid Dendritic Cells , 2007, PLoS biology.

[50]  R. Dummer,et al.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. , 2007, The Journal of clinical investigation.

[51]  C. Rice,et al.  Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients , 2007, The Journal of experimental medicine.

[52]  A. Mantovani,et al.  Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin , 2005, The Journal of experimental medicine.

[53]  H. Ploegh,et al.  UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes , 2008, Nature.

[54]  B. Livingston,et al.  Negative regulation of TLR9‐mediated IFN‐α induction by a small‐molecule, synthetic TLR7 ligand , 2007 .

[55]  Shuhan Sun,et al.  Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. , 2009, Journal of hepatology.

[56]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[57]  M. Colonna,et al.  Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. , 2006, Blood.

[58]  M. Stanley,et al.  Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. , 1999, Antiviral research.

[59]  A. Schneeweiss,et al.  Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. , 2009, Cancer research.

[60]  C. Figdor,et al.  Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. , 2008, Blood.

[61]  Virginia Pascual,et al.  Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.

[62]  M. Grace,et al.  Interferon-alpha as an immunotherapeutic protein. , 2002, Journal of leukocyte biology.

[63]  Sarah E. Ewald,et al.  The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor , 2008, Nature.

[64]  Antonio Lanzavecchia,et al.  BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction , 2001, The Journal of experimental medicine.

[65]  R. Dummer,et al.  Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. , 2005, Journal of the National Cancer Institute.

[66]  S. Lebecque,et al.  Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage1 , 2007, The Journal of Immunology.

[67]  T. Giese,et al.  Tumour‐derived prostaglandin E2 and transforming growth factor‐β synergize to inhibit plasmacytoid dendritic cell‐derived interferon‐α , 2009, Immunology.

[68]  T. Giese,et al.  Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. , 2003, Cancer research.

[69]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[70]  Hideo Negishi,et al.  Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.

[71]  J. Trowsdale,et al.  You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling , 2006, European journal of immunology.

[72]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[73]  M. Oyama,et al.  Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing , 2009, The Journal of experimental medicine.

[74]  Hisao Tajiri,et al.  Cancer immunotherapy by fusions of dendritic cells and tumor cells. , 2009, Immunotherapy.

[75]  M. Lederman,et al.  Impaired Plasmacytoid Dendritic Cell (PDC)-NK Cell Activity in Viremic Human Immunodeficiency Virus Infection Attributable to Impairments in both PDC and NK Cell Function , 2009, Journal of Virology.

[76]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[77]  J. Schroeder,et al.  Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-α , 2008 .

[78]  K. Umezawa,et al.  Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells , 2009, Clinical Cancer Research.

[79]  D. Green,et al.  IgG-derived Fc down-regulates virus-induced plasmacytoid dendritic cell (pDC) IFNalpha production. , 2004, Cytokine.

[80]  Wei Cao,et al.  Plasmacytoid dendritic cell–specific receptor ILT7–FcɛRIγ inhibits Toll-like receptor–induced interferon production , 2006, The Journal of experimental medicine.

[81]  T. Sasazuki,et al.  Spatiotemporal regulation of intracellular trafficking of Toll-like receptor 9 by an inhibitory receptor, Ly49Q. , 2009, Blood.

[82]  Hong Yu,et al.  Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. , 2009, Microbes and infection.

[83]  W. Cao,et al.  Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. , 2006, Blood.

[84]  M. Colonna,et al.  Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. , 2005, Blood.

[85]  G. Stingl,et al.  Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod1 , 2004, The Journal of Immunology.